explore -WSS

explore

author：entertainment 2025-09-06 03:32:48 - browse：17

Pfizer plans to exit a major biotechnology industry trade association. Cindy Ord/Getty Images for Pfizer/BioNTech

WASHINGTON — Pfizer has decided to leave the Biotechnology Innovation Organization, according to two sources familiar with the planning.

The departure is a blow to BIO, which represents members ranging from small biotech startups to massive pharmaceutical companies. The group on Tuesday announced its new CEO, rare disease advocate and biotech executive John Crowley.

“The economic situation for the industry is difficult indeed and we of course are disappointed that any company would be forced to take a break from its BIO membership. We certainly hope that when economic conditions improve, we can welcome those companies back and welcome new members to join us as well, but it in no way affects our mission of protecting patients and medical innovation in the United States,” said BIO’s Chief Public Affairs and Marketing Officer Rich Masters. Masters said he wouldn’t comment on the status of any particular member.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： In Memoriam: Notable people who died in 2023
Next article： Listen: Biotech layoffs, eye drug drama, & gene therapy milestones

WSS

Explaining an after

DeepMind touts AlphaFold's new skills as protein folding AI models face off

Alnylam reports growth in sales of rare disease treatments

Late stage cancers on the rise after pandemic delayed screenings

Group behind ProMed defends move to subscription

Coloradans with cystic fibrosis could lose access to Trikafta

explore

explore

focus

New air purifier tech could be key to improving indoor air quality

Listen: Biotech layoffs, eye drug drama, & gene therapy milestones

After affirmative action ruling, medical educators look to 'holistic review'

Who is Jack Smith, the special counsel overseeing the DOJ's Trump probes?

Novavax promises a turnaround & Lilly roils the obesity market

'Null' research findings aren't empty of meaning. Let's publish them

The cancer drug shortage isn’t new — and neither are the solutions

Who is Jack Smith, the special counsel overseeing the DOJ's Trump probes?

Malaria cases in Florida and Texas: Here’s what you need to know

The a glaring gap in research on serious mental illness and primary care

hotspot

Who is Jack Smith, the special counsel overseeing the DOJ's Trump probes?

Judge partially blocks Texas abortion ban for medical emergencies, fatal diagnoses

Readout LOUD podcast: ESMO highlights & Roivant's big deal

Key Senate panel to consider PBM, drug pricing reform package

Kidney transplant patients stopped immunosuppressants in trial

Explaining an after

knowledge

leisure time

explore

explore